Loading
A phase 2 trial of fruquintinib, tislelizumab, trifluridine/tipiracil and bevacizumab (glioblastoma use) in colorectal cancer, run by Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest, now recruiting.
- IKF/AIO-QUINTIS - Evaluating Fruquintinib in Combination With Tislelizumab in Microsatellite Stable / Proficient Mismatch Repair (MSS/pMMR) Metastatic Colorectal Cancer Without Active Liver Metastases is a phase 2, randomised interventional study registered as NCT06856837 by Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest, with a registry enrolment figure of 140 participants, started 2025-10-27 and due to reach its primary completion in 2029-12-31. Interventions recorded: Fruquintinib; Tislelizumab; Trifluridine/tipiracil; Bevacizumab. Conditions listed: Metastatic Colorectal Cancer. Primary outcome: To evaluate the efficacy of Fruquintinib in combination with the PD-1 inhibitor Tislelizumab in MSS/pMMR metastatic colorectal cancer without liver metastases.. Colorectal eligibility wording from the registry: "Patient has been diagnosed with histologically or cytologically proven microsatellite stable (MSS)/proficient mismatch repair (pMMR) metastatic adenocarcinoma of the colon or rectum, which is not amenable to potentially curative resection". Sites: Austria, Germany. No results are recorded here; the registry entry is the source.
Shares Fruquintinib, Tislelizumab, Anti-angiogenic therapy, Colon cancer (adenocarcinoma of the colon) and the tag colorectal-deep-dive.
Shares Fruquintinib, Bevacizumab (glioblastoma use), Anti-angiogenic therapy, Colon cancer (adenocarcinoma of the colon) and the tag colorectal-deep-dive.
Shares Fruquintinib, Bevacizumab (glioblastoma use), Anti-angiogenic therapy, Colon cancer (adenocarcinoma of the colon) and the tag colorectal-deep-dive.
Shares Tislelizumab, Mismatch-repair deficient (MSI-high) colorectal cancer, Anti-angiogenic therapy, Colon cancer (adenocarcinoma of the colon) and the tag colorectal-deep-dive.
Shares Fruquintinib, Tislelizumab, Anti-angiogenic therapy, Colorectal cancer trials open today (registry snapshot) and the tag colorectal-deep-dive.
Shares Fruquintinib, Anti-angiogenic therapy, Colon cancer (adenocarcinoma of the colon), Colorectal cancer trials open today (registry snapshot) and the tag colorectal-deep-dive.
Shares Fruquintinib, Bevacizumab (glioblastoma use), Anti-angiogenic therapy, Colon cancer (adenocarcinoma of the colon) and the tag colorectal-deep-dive.
Shares Trifluridine/tipiracil, Bevacizumab (glioblastoma use), Anti-angiogenic therapy, Colon cancer (adenocarcinoma of the colon) and the tag colorectal-deep-dive.